Lomond Therapeutics Holdings, Inc.
Clinical trials sponsored by Lomond Therapeutics Holdings, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to tackle tough leukemia Results expected Dec 2026 (estimated)
-
New drug combo aims to tackle tough leukemia
Disease control Recruiting nowThis early-phase study tests a new drug called lonitoclax combined with azacitidine in 66 adults whose acute myeloid leukemia has returned or not responded to prior treatment. The main goal is to find a safe dose and check for early signs that the combination might help control t…
Phase 1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill ZE50-0134 takes on Hard-to-Treat leukemia and lymphoma
Disease control Recruiting nowThis early-stage study is testing a new oral drug called ZE50-0134 in 66 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or certain low-grade lymphomas that have come back or not responded to prior treatments. The main goal is to check the drug's…
Phase 1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for Hard-to-Treat leukemia? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new oral drug, ZE46-0134, in 150 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatment. The study focuses on people with specific gene changes (FLT3 or spliceosome mutations). The main goals are to check safe…
Phase 1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC